Loss of constitutional heterozygosity on chromosomes 5 and 17 in cholangiocarcinoma S.-F. Ding Summary It has been established that loss of tumour suppressor genes is crucial in carcinogenesis. There has been no reported study on searching for tumour suppressor genes in cholangiocarcinomas as yet. In order to investigate the loss of heterozygosity (LOH), which may represent such gene loss, in cholangiocarcinoma, we studied 14 patients with this tumour using restriction fragment length polymorphism analysis. Twenty-two probes assigned to chromosomes 1, 5, 7, 9, 11, 12, 13, 14, 16, 17 and 18 were used. Allelic losses were found in chromosomal regions 5q35-qter and l7pl3. Loss of genetic material in these regions in cholangiocarcinoma was shared with hepatocellular carcinoma. Probes for other chromosomes have as yet shown no consistent LOH. In conclusion, this study for the first time showed LOH on chromosomes 5 and 17 in cholangiocarcinoma.
Cholangiocarcinoma, the intrahepatic bile duct carcinoma, is thought to arise from the same stem cell as hepatocellular carcinoma (HCC) (Sell & Dunsford, 1989) . Cholangiocarcinoma is reported as occurring less frequently than HCC in most parts of the world. The prognosis of cholangiocarcinoma is poor, with the majority of patients dying 6-12 months after diagnosis. The overall survival rate in treated cases at 5 years is below 9% (Czerniak & Blumgart, 1989) .
There is a growing realisation that cancer is a set of fundamentally genetic diseases (Lasko et al., 1991 (Friend et al., 1986) , p53 (Oren et al., 1981) , WTI (Call et al., 1990) , NFl (Wallace et al., 1990; Viskochil et al., 1990; Cawthon et al., 1990) and APC (Kinzler et al., 1991a; Groden et al., 1991) genes. DCC was clones and could prove to be a candidate suppressor gene (Fearon et al., 1990 (Lasko et al., 1991) . A variety of tumours, including both childhood and common adult malignancies, exhibit LOH (Lasko et al., 1991) .
Expression of oncogenes, including ras, myc and erbB-2, and point mutations at K-ras codons 12 and 61 have been reported in a high proportion of cholangiocarcinomas (Voravud et al., 1989; Tada et al., 1990) . Cytogenetic studies on two cholangiocarcinoma cell lines revealed several chromosomal abnormalities (Storto et al., 1990) . To our knowledge, however, there has been no reported study of loss of heterozygosity in cholangiocarcinomas as yet. Here we report the first study of LOH in cholangiocarcinoma with 22 RFLP probes assigned to 11 chromosomes.
Materials and methods
Patients and biopsies Fourteen patients with cholangiocarcinoma were studied. All underwent resection of their tumours. None of the patients received chemotherapy or radiotherapy before surgery. Surgical biopsies from tumoral and non-tumoral liver tissues were snap frozen in liquid nitrogen at the time of operation. Lymphocytes from peripheral blood obtained pre-operatively were also used as a source of normal DNA. Tissue was stored at -70°C until DNA extraction. A portion of each tumour sample was examined histologically to confirm the type of tumour present.
DNA extraction and analysis DNA was prepared from blood and tissue samples by standard phenol/chloroform methods (Sambrook et al., 1989) . Southern analyses were done as previously described (Ding et al., 1991) . The 22 RFLP probes for chromosomes 1, 5, 7, 9, 11, 12, 13, 14, 16, 17 and 18 and the appropriate restriction enzymes are listed in Table I . If two alleles appeared as two separate bands in the resultant autoradiograph of the constitutional DNA, the patient was considered 'informative', or heterozygous, for the particular marker. Complete deletion or loss of intensity of one band in the tumour DNA indicated an allele loss, or an LOH. The loss of band intensity was confirmed by examination of the autoradiographs with densitometry. A cutoff level of 50% or more of allele intensity was considered as evidence of LOH.
Results Table I shows the overall pattern of allele loss in cholangiocarcinoma. Overall, 164/229 Southern blots were informative (heterozygosity: 71.6%) and the overall LOH was 17 out of 164 informative cases (10.4%). Figure 1 shows representative examples of allele loss.
As shown in Table I probes for chromosome 5q, including a genomic probe L5-71-3 for MCC and a cDNA probe, 54-D, for APC. Table II shows that patients with cholangiocarcinoma had no allele loss when screened with probes mapped to regions of the chromosome other than 5q35-qter. On the other hand the majority of patients with hepatic metastases from colorectal cancers showed allele loss with probes from 5q21-22, the region of the chromosome associated with colorectal cancer.
Discussion
This is the first study on loss of heterozygosity in cholangiocarcinomas. Three out of 22 probes revealed a relatively high rate of LOH in two chromosomal regions, namely, 5q35-qter (30%) and 17pl3 (44.4% and 40%). There were also allelic losses at 'p33-35 (2/14, 14.3%), lq42-43 (23.1%), 7pter-q22 (1/13, 7.7%), 9q34 (1/11, 9.1%) and 12q24.3-qter (1/11, 9.1%), but these lower values might represent random losses since rapid division of malignant cells can produce loss of heterozygosity at a certain region by chance (Lasko et al., 1991) . We have previously reported allelic losses at lq42-43 and 17p13 in hepatocellular carcinoma with liver cirrhosis and at 5q35-qter and 17p13 in HCC without liver cirrhosis (Ding et al., 1991) . Hence it is of interest to find LOH at 5q35-qter and 17p13 in cholangiocarcinoma in this study. It has been proposed that HCC and cholangiocarcinoma arise from the same pluripotent liver stem cell (Sell & Dunsford, 1989) . These two types of primary liver malignancies, therefore, may share similar genetic changes. Allele loss on chromosome 17p is shared with other tumours and may be involved in 'tumour progression' (Sager, 1989; Lasko et al., 1991) .
Loss of heterozygosity at 5q35-qter in both HCC and cholangiocarcinoma thus might represent a common genetic change in the development of the two tumours. Further study is needed to confirm this finding. This investigation reports the results of 14 patients collected simultaneously from two active liver centres over 3 years. The scarcity of this material highlights the difficulty of surgical resection of intrahepatic cholangiocarcinoma. Most patients present usually at such an advanced stage that precludes surgical resection. The familial adenomatous polyposis coli (APC) gene is located at 5q21 and the gene has been cloned (Kinzler et al., 1991a; Groden et al., 1991) . We previously compared the pattern of allele loss in non-cirrhotic HCC with that of hepatic metastases from colorectal cancers using various probe for chromosome 5q (Ding et al., 1991) . The majority of LOH in hepatic metastases from colorectal cancers was found at the region 5q21-22 while the LOH in non cirrhotic HCC was at 5q35-qter. In the present study on cholangiocarcinomas allele loss also occurred at 5q35-qter. However, probes from 5q21-22, including a cDNA probe from APC gene, did not show any allele loss in cholangiocarcinoma (Tables I and II) . The possible common region involved in both HCC and cholangiocarcinoma appears to be distinct from that encompassing APC. This is supported by the finding that the three patients exhibiting allele loss at 5q35-qter with the probe AMS8 have shown no allele loss with the probe 54-D from the APC gene.
There has been no reported direct cytogenetic study as yet on cholangiocarcinoma tissue. Chromosome study on two cholangiocarcinoma cell lines showed a number of abnormalities (Storto et al., 1990) . It is of particular interest that chromosome 5 was among the most commonly involved chromosomes in structural abnormalities in both cell lines. This finding and the results of RFLP analysis in this study suggest that mutation or deletion of a possible tumour suppressor gene located on chromosome 5, distal to 5q21-22, may play a role in the development of cholangiocarcinoma.
Recently, loss or mutation of the p53 tumour suppressor gene at chromosome 17p has been seen at a very high frequency in a variety of human malignancies (Weinberg, 1991) . Loss of heterozygosity occurred in four out of nine cholangiocarcinoma shown by p144-D6, and in two of five shown by pYNZ22, in this study. Both probes are assigned to the region of l7pl3, near the locus of the p53 tumour suppressor gene. This finding makes it likely that loss of the p53 gene is also involved in the development of cholangiocarcinoma. It will be of interest to know if there is any overexpression of mutant p53 or point mutation of the p53 gene in cholangiocarcinoma.
In conclusion, this study showed allelic losses on chromosomes 5q35-qter and 17pl3 in cholangiocarcinoma. These losses are shared with HCC.
